Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2021-09-08 Share Issue/Capital Cha…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - IMU 8 pages 30.1KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Application for quotation of +securities' and details the application for quotation of securities issued by Imugene Limited. It includes information about the number and type of securities to be quoted, issue dates, and references to previous announcements such as Appendix 3B filings. The document is an official announcement to the ASX regarding the quotation of securities already issued, not a financial report or detailed analysis. It does not contain financial statements or management discussion but is a regulatory announcement related to capital market activities. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is 6391 characters, which is consistent with a detailed announcement but not a full report.
2021-09-08 English
Results of Meeting 2 pages 136.3KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX announcement titled 'RESULTS OF EXTRAORDINARY GENERAL MEETING' dated 7 September 2021. It reports the voting results of resolutions passed at an Extraordinary General Meeting (EGM), including detailed proxy votes and poll results. The content focuses on the official results of shareholder votes at a general meeting, which aligns with the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is 2565 characters, which is relatively short and consistent with a voting results announcement rather than a full meeting report or proxy solicitation. There is no indication of it being a full Annual Report, Management Report, or other types of filings. Therefore, the correct classification is DVA with high confidence.
2021-09-06 English
Proposed issue of securities - IMU 5 pages 28.0KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by IMUGENE LIMITED. It details the number of securities to be issued, the issue price, the approval by shareholders at an Extraordinary General Meeting, and other specifics related to the placement or issue of shares. There is no financial performance data, management discussion, or audit information. The document is focused on capital raising activities and changes in the company's capital structure. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive announcement about a financing event.
2021-09-06 English
Application for quotation of securities - IMU 9 pages 32.3KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, prices, and the resulting capital structure. There is no indication of financial performance data, management discussion, or regulatory certifications. The content focuses on the issuance and quotation of new shares following option exercises, which aligns with announcements about share issues or capital changes. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length (8417 characters) and detailed issuance data confirm it is not a brief announcement or a report publication notice but a substantive filing about capital changes.
2021-09-02 English
Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials 3 pages 157.8KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement from Imugene Limited dated 01 September 2021. It reports clinical trial data for the HER-Vaxx Phase 2 gastric cancer trial, including secondary efficacy endpoint progression free survival (PFS) data, safety information, and plans for new trials. The content focuses on clinical trial results and future study plans rather than financial results or regulatory filings. There is no indication that this is a full financial report, audit report, or earnings release. It is a corporate announcement about clinical trial progress and future plans, which fits best under Capital/Financing Update (CAP) as it relates to company progress and potential impact on capital markets, or possibly Regulatory Filings (RNS) as a general announcement. However, since it is a clinical trial data announcement and plans for new trials, it is more aligned with Capital/Financing Update (CAP) because such announcements often impact investor decisions and company valuation. The document length is 5556 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the best classification is CAP with high confidence.
2021-08-31 English
Appendix 4E and Full Year Statutory Accounts 86 pages 2.0MB
Annual Report Classification · 95% confidence The document is titled 'Imugene Limited Appendix 4E Year ended 30 June 2021' and contains detailed financial results for the year ended 30 June 2021, including revenue, net loss, net tangible assets, and changes in controlled entities. It also includes an audit statement indicating the financial statements have been audited without qualification. The document contains a comprehensive review of operations and activities, directors' report, financial statements, and an independent auditor's report. The length is substantial (15,000 characters), and it includes actual financial data and analysis for the full fiscal year. Appendix 4E is an Australian Securities Exchange (ASX) form used for preliminary final reports, which is effectively an annual report or full year financial report. Given the detailed financial statements, audit report, and management discussion, this document fits the definition of an Annual Report (10-K equivalent). It is not merely an announcement or a certification, but a full audited financial report for the year ended 30 June 2021. FY 2021
2021-08-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.